Drug Use Research & Management Program
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119

DRUG USE REVIEW BOARD - MEETING MINUTES
Division of Medical Assistance Programs – State of Oregon
Thursday, September 18, 2008 2:00-5:00 PM
Clackamas Community Training Center Rm 110

1) CALL TO ORDER

Members present: Rickland G Asai, DMD; Maggie Bennington-Davis, MD; Patrick Bowman, RPh; Laura DeSimone, RPh; Fara Etzel, MD; Dean Haxby, PharmD; Jordan Laub, MD, MPH. **Members Present by Phone:** Sherry Barrett, RPh; George Gerding, RPh; David Evans, MD; Kyle Johnson, MD. **Members Not Present:** Robert M Ingle, Jr., MD, MPH; **Staff** Present: Cydreese Aebi (OSU); Rose-Ellen Hope, RPh (OSU); Kathy Ketchum (OSU); Luke Middleton (OSU); Ralph Magrish (DMAP) Cheryl Schollenberg (DMAP) Terri Shultz (CAF). **Guests present:** Mariellen Rich (EDS) Felicia Fuller (Biogen Idec); Dane Roberts (Lilly); Aaron Howe (Gilead): Matt Krebs(Pfizer); Bridget Hedquist (student); Jeff Costello (student) Barry Benson (Merck); Diann Matthews (J&J)

a) Mr. Bowman called the meeting to order at approximately 2:10 PM. Attendees were introduced.
b) Membership was reviewed. Dr. Kyle Johnson and Ms. Sherry Barrett have resigned at the end of their terms (Sept 08). Dr. Asai has given notice of his resignation in 2010. Ms. Laura DeSimone agreed to serve another 2-year term as did Dr. Jordan Laub. Recruiting will begin for the academic physician and retail pharmacist positions immediately.
c) The Conflict of Interest Declaration as reviewed. One members renewed their declarations.
d) The May minutes were approved with no corrections.
e) The meeting agenda was approved.
f) Written public comment from Pfizer and Dr. Charles Bentz from Providence Smoking Cessation were reviewed.

ACTION: Recommend seek permission from Providence to adapt the risk tool for posting on the DUR website “Prescriber Tools” page.

2) OLD BUSINESS

a) Smoking Cessation Policy Proposal Update: Dr. Aebi reported the May DUR Board concerns about sharing patient data with the Quit Line prior to patient notice with the DMAP Disease State Management (DSM) unit. The DSM unit is clear that the proposed data-sharing is appropriate under HIPPA regulations and is eager to enhance outreach efforts to facilitate Medicaid patients in their quit smoking efforts. The DSM unit asked the DUR Board to reconsider their recommendations given it is typical of the DSM unit to call at risk patients and invite them to join various programs (e.g. COPD, Asthma). The unit suggested wording and heading changes so as not to give the appearance that data had been shared inappropriately. Dr. Haxby reported that CareOregon runs a similar program with the Quit Line that has been quite successful.

ACTION: Recommend the program move forward with wording changes.

b) DHS Medication Management / CAF Request: Terry Schultz from Children, Adults and Families (CAF) provided background on a request from the Interim Director, Erinn Kelley-Siel for the DUR Board to review and comment on criteria to identify foster children that may need additional medical review for their psychotropic drug use. Dr. Aebi presented a literature review focused on the available medical evidence for psychotropic drug use in children. The Board had a lengthy and substantive discussion that included general comment on the foster care and medical coverage systems such as poor access to mental health providers, slow

response from case-workers, fragmented medical histories and generally challenging situations. However, there was general agreement the existing CAF criteria, with some modifications, was a reasonable way to identify children that needed additional medical review.

ACTION: Draft letter with detailed recommendations to Ms. Kelley-Siel (see attached).

ACTION: Recommend adapting criteria and apply in the Polypharmacy Review Program for all OHP children.

c) Chronic Benzos in the Elderly: Ms. Hope presented a summary of DUR Board actions on this topic with a proposed RetroDUR intervention.

ACTION: Recommended proceed with intervention and exclude patients on Diastat with seizures.

d) BPH PA Criteria Revision: Dr. Aebi presented changes discussed at May meeting.

3) NEW BUSINESS

a) Allergy Drug PA Revision: Ms. Hope presented proposed changes to these criteria which were updated to be consistent with current treatment guidelines, the OHP prioritized list and add certirizine to the list of drugs available without PA.

ACTION: Recommended criteria changes be accepted.

b) GH PA Revision: Dr. Aebi presented a summary of new literature and recommended changes.

ACTION: Recommended criteria changes be accepted.

4) REPORTS

a) DMAP Pharmacy Program Report: Mr. Magrish reported here will be more pharmacy trainings with the new MMIS system and updated members on tamper resistant prescription pads information.

ACTION: Websites for this information to be forwarded to the members.

b) CMS Annual Report FFY 07-08: Mr. Magrish presented the report that was sent to CMS in June. This includes information previously reported to the DUR Board.

c) Drug Utilization Trend Report - Ms. Ketchum presented the report

d) Retro DUR Report: Ms. Hope presented the RetroDUR report.

e) Prescriber tools:

i) DUR Newsletter: Dr. Aebi reported newsletters on heart failure management, drug safety and treatment resistant depression were published in May, July and Aug. September will be on neuropathic pain and next month the newsletter will be on an antibiotic program from OHSU.

ii) ePocrates: Ms. Ketchum present quarterly utilization numbers have flattened out but have received consistently good comments on the availability of this service.

iii) Pocket Drug Guide: Ms. Ketchum reported revision is due. There was discussion as to the usefulness of this tool given the ePocrates uptake.

f) OHPR Report

i) HRC/DERP: Dr. Aebi updated which drug reports being considered by HRC/DERP.

ii) HSC : Ms. Ketchum reported there will be 340 changes to the list 10/1/08. There are new guidelines for cervical dysplasia, bariatrics, PET scans, MTM codes, and the sleep apnea criteria was revised.

Meeting adjourned at approximately 3:45.
Next meeting is Thursday Dec 4 in Salem